Article tools
Author information
Published in Volume 64, Issue 2 (August , 1979)
J. Clin. Invest. 64(2): 398-404 (1979). doi:10.1172/JCI109475.
Copyright © 1979, The American Society for Clinical Investigation

Articles

Endocrine Consequences of Continuous Antiestrogen Therapy with Tamoxifen in Premenopausal Women

Barry M. Sherman, Frederick K. Chapler, Kent Crickard and Dorothy Wycoff

Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa 52242 Department of Obstetrics and Gynecology, University of Iowa College of Medicine, Iowa City, Iowa 52242 Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242

Published August , 1979

Daily administration of estrogen antagonists to premenopausal women has been incorporated into the adjuvant treatment of breast cancer. We have studied the changes in reproductive hormones, pituitary responses to hypothalamic-releasing hormones, and endometrial histology during treatment with the antiestrogen tamoxifen in five healthy, premenopausal women. These studies were carried out during one menstrual cycle before and during two cycles of antiestrogen treatment. All subjects continued to have regular menses with biphasic basal body temperature records. During treatment, estradiol (E2) levels were increased but followed the usual pattern reflecting follicular maturation and corpus luteum formation. The mean E2 concentration at the midcycle peak and during the luteal phase was twice that observed during the non-treatment cycle. By contrast, the concentrations and secretory patterns of luteinizing hormone and follicle-stimulating hormone were not greatly changed, and the gonadotropin responses to gonadotropin-releasing hormone were not suppressed.

Endometrial biopsies obtained during the follicular phase of control and tamoxifen treatment cycles showed no differences whereas biopsies obtained during the luteal phase of tamoxifen cycles uniformly showed a lack of changes attributed to progesterone action with no progression of histologic changes beyond those expected on day 7-8 of the luteal phase.

These observations are consistent with maturation of multiple ovarian follicles, a surprising finding considering the normal gonadotropin concentrations. The retarded development of the endometrium in the presence of supranormal serum E2 and progesterone concentrations is a morphologic demonstration of the antiprogestational effect of antiestrogens. The lack of gonadotropin suppression in the presence of hyperestrogenemia suggests a major antiestrogen action on the hypothalmus and pituitary gland.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 398
icon of scanned page 399
icon of scanned page 400
icon of scanned page 401
icon of scanned page 402
icon of scanned page 403
icon of scanned page 404

This article Copyright © 1979, The American Society for Clinical Investigation.

Articles that cite this article:

BLOCKAGE OF THE POSITIVE FEEDBACK EFFECT OF OESTRADIOL DURING PROLONGED ADMINISTRATION OF CLOMIPHENE CITRATE TO NORMAL WOMEN
IOANNIS E. Messinis, ALLAN Templeton
Clin Endocrinol (Oxf) 29(5):509. doi:10.1111/j.1365-2265.1988.tb03700.x [CrossRef]

The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer
Tadaki Yasumura, Toshikazu Akami, Manabu Mitsuo, Takahiro Oka, Kazuo Naitoh, Takara Yamamoto, Hideo Honjyo, Hiroji Okada
Japanese Journal of Surgery 20(4):369. doi:10.1007/BF02470819 [CrossRef]

TAMOXIFEN PROLONGS LUTEAL PHASE IN PREMENOPAUSAL WOMEN BUT HAS NO EFFECT ON THE SIZE OF UTERINE FIBROIDS
M. A. Lumsden, C. P. West, D. T. Baird
Clin Endocrinol (Oxf) 31(3):335. doi:10.1111/j.1365-2265.1989.tb01257.x [CrossRef]

The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole
V. Craig Jordan
Breast Cancer Res Tr 11(3):197. doi:10.1007/BF01807278 [CrossRef]

Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma
Richard J. Santen, Andrea Manni, Harold Harvey
Breast Cancer Res Tr 7(3):129. doi:10.1007/BF01806244 [CrossRef]

Current Status of Hormonal Therapy of Fibrocystic Breast Disease
L. Dogliotti, P. Fioretti, G. B. Melis, A. Mussa, A. Angelai
Ann N Y Acad Sci 464(1 endocrinology):350. doi:10.1111/j.1749-6632.1986.tb16014.x [CrossRef]

Comparison of Tamoxifen and Bromocriptine in Management of Fibrocystic Breast Disease: A Randomized Blind Study
S. Sandrucci, A. Mussa, V. Festa, A. BorrÈ, M. Grosso, L. Dogliotti
Ann N Y Acad Sci 464(1 endocrinology):626. doi:10.1111/j.1749-6632.1986.tb16090.x [CrossRef]

Chemohormonal therapy and endocrine function in breast cancer patients
Ann M. Dnistrian, Ernest J. Greenberg, Hildy J. Dillon, Thomas B. Hakes, Alfred A. Fracchia, Morton K. Schwartz
Cancer (Philad ) 56(1):63. doi:10.1002/1097-0142(19850701)56:1<63::AID-CNCR2820560111>3.0.CO;2-7 [CrossRef]

Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer
Jan G. M. Klijn, Frank H. Jong, Marinus A. Blankenstein, Roel Docter, Jana Alexieva-figusch, Joan Blonk Wijst, Steven W. J. Lamberts
Breast Cancer Res Tr 4(3):209. doi:10.1007/BF01806487 [CrossRef]

Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy. Case report
SIMON S. Cross, SEZGIN M. Ismail
BJOG An Internal Journal of Obs Gyn 97(2):190. doi:10.1111/j.1471-0528.1990.tb01748.x [CrossRef]

Effects of estradiol and some antiestrogens (Clomiphene, tamoxifen, and hydroxytamoxifen) on luteinizing hormone secretion by rat pituitary cells in culture
G. Emons, O. Ortmann, Sabine Thiessen, R. Knuppen
Arch Gynecol 237(4):199. doi:10.1007/BF02133782 [CrossRef]

Clinical Uses of Antiestrogens
Valerie L. Baker, Robert B. Jaffe
Obstet Gynecol Surv 51(1):45. doi:10.1097/00006254-199601000-00021 [CrossRef]

Plasma hormone responses to tamoxifen therapy and oophorectomy
Adel S. Al-jurf
J Surg Oncol 21(4):271. doi:10.1002/jso.2930210417 [CrossRef]

Response of advanced breast cancer to total endocrine ablation after exacerbation on tamoxifen: Results in seven patients and possible mechanism of action
Jack W. Hartley, Jan Wong, William S. Fletcher
J Surg Oncol 34(3):182. doi:10.1002/jso.2930340311 [CrossRef]

Gynaecologic effects of tamoxifen
Dennis Yi-Shin Kuo, Carolyn D. Runowicz
MO 12(2):87. doi:10.1007/BF01676708 [CrossRef]

Tamoxifen and the female reproductive tract
Sharon L Mount, Gamal H Eltabbakh
Expert Opin Pharmacother 2(9):1399. doi:10.1517/14656566.2.9.1399 [CrossRef]